{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:55:03Z","timestamp":1765886103063,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["PP150079"],"award-info":[{"award-number":["PP150079"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12916-017-0969-3","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T07:38:44Z","timestamp":1510731524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study"],"prefix":"10.1186","volume":"15","author":[{"given":"Christina","family":"Yek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"de la Flor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Zoellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Mayorga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamta K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"issue":"5","key":"969_CR1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","volume":"62","author":"BR Edlin","year":"2015","unstructured":"Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353\u201363.","journal-title":"Hepatology"},{"issue":"3","key":"969_CR2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"969_CR3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","volume":"62","author":"KN Ly","year":"2016","unstructured":"Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287\u20138.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"969_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469\u201377.","journal-title":"J Infect Dis"},{"issue":"18","key":"969_CR5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.2014.12627","volume":"312","author":"AJ Meer van der","year":"2014","unstructured":"van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, Janssen HL. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312(18):1927\u20138.","journal-title":"JAMA"},{"issue":"24","key":"969_CR6","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584\u201393.","journal-title":"JAMA"},{"issue":"9286","key":"969_CR7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958\u201365.","journal-title":"Lancet"},{"issue":"6","key":"969_CR8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631\u201340.","journal-title":"JAMA"},{"issue":"10","key":"969_CR9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1136\/gutjnl-2016-311609","volume":"66","author":"TM Welzel","year":"2017","unstructured":"Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2017;66(10):1844\u201352.","journal-title":"Gut"},{"issue":"2","key":"969_CR10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","volume":"150","author":"MS Sulkowski","year":"2016","unstructured":"Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150(2):419\u201329.","journal-title":"Gastroenterology"},{"issue":"6","key":"969_CR11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","volume":"151","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131\u201340. e1135.","journal-title":"Gastroenterology"},{"issue":"5","key":"969_CR12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/liv.13036","volume":"36","author":"AA Butt","year":"2016","unstructured":"Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int. 2016;36(5):651\u20138.","journal-title":"Liver Int"},{"issue":"5","key":"969_CR13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","volume":"160","author":"MM Denniston","year":"2014","unstructured":"Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293\u2013300.","journal-title":"Ann Intern Med"},{"issue":"12","key":"969_CR14","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1007\/s10620-016-4340-x","volume":"61","author":"KR Beck","year":"2016","unstructured":"Beck KR, Kim N, Khalili M. Sofosbuvir-containing regimens for chronic hepatitis C are successful in the safety-net population: a real-world experience. Dig Dis Sci. 2016;61(12):3602\u20138.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"969_CR15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/jama.294.10.1248","volume":"294","author":"BR Asplin","year":"2005","unstructured":"Asplin BR, Rhodes KV, Levy H, Lurie N, Crain AL, Carlin BP, Kellermann AL. Insurance status and access to urgent ambulatory care follow-up appointments. JAMA. 2005;294(10):1248\u201354.","journal-title":"JAMA"},{"issue":"6","key":"969_CR16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2016","unstructured":"Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683\u201394.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"969_CR17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","volume":"62","author":"S Saeed","year":"2016","unstructured":"Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferriere V, Hull M, Gill MJ, Cox J, Cooper C, et al. How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world? Clin Infect Dis. 2016;62(7):919\u201326.","journal-title":"Clin Infect Dis"},{"key":"969_CR18","unstructured":"AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. \nhttps:\/\/www.hcvguidelines.org\/\n\n. Accessed 17 June 2017."},{"issue":"2","key":"969_CR19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2893.2002.00341.x","volume":"9","author":"T Poynard","year":"2002","unstructured":"Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9(2):128\u201333.","journal-title":"J Viral Hepat"},{"issue":"11","key":"969_CR20","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/j.1572-0241.2007.01466.x","volume":"102","author":"AA Shaheen","year":"2007","unstructured":"Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102(11):2589\u2013600.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"969_CR21","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.27736","volume":"61","author":"AJ Leidner","year":"2015","unstructured":"Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860\u20139.","journal-title":"Hepatology"},{"issue":"5","key":"969_CR22","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/hep.28018","volume":"62","author":"BJ Turner","year":"2015","unstructured":"Turner BJ, Taylor BS, Hanson J, Liang Y, Veerapaneni P, Villarreal R, Perez M, Hernandez L, Sandhu J, Fiebelkorn K. High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers. Hepatology. 2015;62(5):1388\u201395.","journal-title":"Hepatology"},{"issue":"6","key":"969_CR23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamainternmed.2017.0358","volume":"177","author":"JA Barocas","year":"2017","unstructured":"Barocas JA, Beiser M, Leon C, Gaeta JM, O\u2019Connell JJ, Linas BP. Experience and outcomes of hepatitis C treatment in a cohort of homeless and marginally housed adults. JAMA Intern Med. 2017;177(6):880\u20132.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"969_CR24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MEG.0000000000000755","volume":"29","author":"EM Nordstrom","year":"2017","unstructured":"Nordstrom EM, Keniston A, Baouchi F, Martinez-Camacho A. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety. Eur J Gastroenterol Hepatol. 2017;29(1):10\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"969_CR25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1572-0241.2006.00682.x","volume":"101","author":"S Verma","year":"2006","unstructured":"Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A. More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol. 2006;101(8):1817\u201323.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"969_CR26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","volume":"131","author":"HS Conjeevaram","year":"2006","unstructured":"Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470\u20137.","journal-title":"Gastroenterology"},{"issue":"3","key":"969_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMoa0805062","volume":"360","author":"M Rodriguez-Torres","year":"2009","unstructured":"Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360(3):257\u201367.","journal-title":"N Engl J Med"},{"issue":"4","key":"969_CR28","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/hep.23429","volume":"51","author":"P Feuerstadt","year":"2010","unstructured":"Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, Pellecchia A, Wolkoff AW, Gaglio PJ, Reinus JF. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology. 2010;51(4):1137\u201343.","journal-title":"Hepatology"},{"issue":"3","key":"969_CR29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","volume":"163","author":"S Barua","year":"2015","unstructured":"Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215\u201323.","journal-title":"Ann Intern Med"},{"issue":"2","key":"969_CR30","first-page":"107","volume":"23","author":"Z Younossi","year":"2017","unstructured":"Younossi Z, Gordon SC, Ahmed A, Dieterich D, Saab S, Beckerman R. Treating Medicaid patients with hepatitis C: clinical and economic impact. Am J Manag Care. 2017;23(2):107\u201312.","journal-title":"Am J Manag Care"},{"issue":"9","key":"969_CR31","doi-asserted-by":"crossref","first-page":"e003231","DOI":"10.1136\/bmjopen-2013-003231","volume":"3","author":"AG Singal","year":"2013","unstructured":"Singal AG, Dharia TD, Malet PF, Alqahtani S, Zhang S, Cuthbert JA. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open. 2013;3(9):e003231.","journal-title":"BMJ Open"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-017-0969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T07:39:07Z","timestamp":1510731547000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-017-0969-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1186\/s12916-017-0969-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"type":"electronic","value":"1741-7015"}],"subject":[],"published":{"date-parts":[[2017,11,20]]},"article-number":"204"}}